Tag: biologic_drugs
-
FTC Files Brief Challenging Amgen's Enbrel Monopoly
The FTC has filed an amicus brief in an antitrust case, alleging Amgen illegally extended its monopoly on the biologic drug Enbrel through exclusive patent acquisitions, aiming to protect competition in drug markets.
Politics and GovernmentBusinessHealthFederal GovernmentEconomyMedical ScienceLegal Federal Trade CommissionAmgenEnbrelAntitrustBiologic DrugsPatentsMonopoly